Back to mobile site

Leerink Partners Reiterates Market Perform Rating on Neogenomics (NEO) amid test reimbursements

March 16, 2026 8:28 AM EDT Send to a Friend
Leerink Partners analyst Puneet Souda reiterated a Market Perform rating and $14.00 price target on Neogenomics (NASDAQ: NEO)The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login